ArticleCureus2025
Paraoxonase 1 Enzyme Activity in Patients With Isolated Coronary Artery Ectasia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveParaoxonase 1 (PON1) is an organophosphate ester hydrolase associated with high-density lipoprotein (HDL). The recently emphasized function of PON1 activity is its antiatherogenic activity. PON1 is always found together with HDL in plasma, and PON1 is responsible for the protective effect of HDL against low-density lipoprotein (LDL) oxidation. Considering this role in cardiovascular diseases and its antioxidant properties, PON1 activity may be a valuable biomarker in predicting coronary artery ectasia (CAE), whose pathogenesis has not yet been fully elucidated. The aim was to reveal the relationship between PON1 activity and isolated CAE.
methodThis prospective case-control study's population comprises 5240 patients who underwent coronary angiography between December 2009 and April 30, 2010. Thirty patients with isolated CAE (Group CAE) and 25 volunteers with normal coronary arteries (Group Control) who met the inclusion criteria were included in the study. The sociodemographic, clinical, and anatomical characteristics and lipid profiles of the patients were analyzed. Groups CAE and control were compared in terms of PON1 activity levels.
resultsThere was no significant difference between Group CAE (n=30) and Group Control (n=25) in terms of sociodemographic and clinical characteristics (p>0.05). There was ectasia in a single coronary artery in 19 patients (63.3%). The right coronary artery (RCA) was ectasian in 17 patients (38.6%) and was the most affected vessel. According to the Markis classification, the most common type of ectasia was type IV ectasia, which was seen in 14 patients (46.7%). When lipid profiles were compared, no difference was observed between the groups. PON1 activity levels were significantly lower in the CAE group than in the control group (Group CAE=127.5 U/L; Group Control=177.0 U/L; p<0.001).
conclusionsThis study's findings suggest a significant correlation between low PON1 activity levels and the development of isolated CAE, suggesting that PON1 activity may play a potential role in the pathophysiology of CAE. Based on the association demonstrated between isolated CAE and PON1 activity in our study, future research may investigate the potential use of PON1 as a biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.